KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Change in Receivables (2016 - 2022)

TherapeuticsMD's Change in Receivables history spans 13 years, with the latest figure at -$13.6 million for Q3 2022.

  • For Q3 2022, Change in Receivables fell 439.82% year-over-year to -$13.6 million; the TTM value through Sep 2022 reached -$4.3 million, down 130.19%, while the annual FY2021 figure was $4.3 million, 47.39% down from the prior year.
  • Change in Receivables reached -$13.6 million in Q3 2022 per TXMD's latest filing, down from $11.1 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $11.1 million in Q2 2022 to a low of -$13.6 million in Q3 2022.
  • Average Change in Receivables over 5 years is $1.6 million, with a median of $790885.0 recorded in 2018.
  • Peak YoY movement for Change in Receivables: tumbled 2767.32% in 2018, then skyrocketed 48326.09% in 2022.
  • A 5-year view of Change in Receivables shows it stood at -$1.8 million in 2018, then soared by 629.91% to $9.3 million in 2019, then fell by 7.4% to $8.6 million in 2020, then crashed by 114.32% to -$1.2 million in 2021, then tumbled by 1006.81% to -$13.6 million in 2022.
  • Per Business Quant, the three most recent readings for TXMD's Change in Receivables are -$13.6 million (Q3 2022), $11.1 million (Q2 2022), and -$489000.0 (Q1 2022).